Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 8/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.69 |
| ▸ | SERPINE1 | P05121 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.67 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.67 |
| ▸ | ACLY | P53396 | 1/20 | 0.63 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.61 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308714 | 0.92 | MEN1 (0.76) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL14075267 | 0.91 | SERPINE1 (0.80) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL1308515 | 0.91 | GRIK1 (0.80) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL2272049 | 0.88 | ACLY (0.78) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL674168 | 0.88 | KCNMA1 (0.66) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL6351321 | 0.87 | SERPINE1 (0.89) | GRIK1MEN1PKMKMT2AKCNMA1 | |
| SCHEMBL1307456 | 0.86 | GRIK1 (0.67) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL2276482 | 0.86 | ACLY (0.74) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL14075271 | 0.86 | GRIK1 (1.00) | GRIK1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL5146969 | 0.85 | SERPINE1 (0.63) | GRIK1MEN1PKMKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | GRIK1 2986/4885MEN1 2312/4885PKM 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.